Pharmaceuticals APAC News & Press Release Distribution

AffaMed Therapeutics Announces New Drug Application Acceptance by Singapore Health Sciences Authority (HSA) for DEXTENZA® for Treatment of Ocular Inflammation and Pain Following Ophthalmic Surgery, and Ocular Itching Associated with Allergic Conjunctivitis

SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- AffaMed Therapeutics ("AffaMed"), a biotechnology company dedicated to developing and commercializing transformative pharmaceutical, and surgical products that address critical unmet medical needs in ophthalmology, today announced that the Singapore Health ...

2024-02-19 09:00 3089

Everest Medicines Announces Termination of Collaboration Agreements with Providence

-Everest will continue to develop self-discovered products utilizing the mRNA platform- SHANGHAI, Feb. 19, 2024 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the development, manufacturing and commercialization of innovative...

2024-02-19 08:20 1588

Pierre Fabre Laboratories and the EspeRare Foundation to be honored with the EURORDIS Company Award for Patient Engagement 2024, in their approach to co-developing a treatment for XLHED.

CASTRES, France and GENEVA, Feb. 15, 2024 /PRNewswire/ -- On February 20, International Ectodermal Dysplasias Awareness Day, Pierre Fabre Laboratories and the EspeRare Foundation will receive the EURORDIS Company Award for Patient Engagement 2024, at the EURORDIS Black Pearl Award Ceremony to be ...

2024-02-15 17:05 1762

Brii Biosciences Announces Agreement to Acquire VBI's IP Rights in BRII-179 (VBI-2601) and Plans to Initiate Technology Transfer to Expand Clinical and Commercial Supplies

Acquiring all intellectual properties relating to BRII-179 and eliminating future milestone and royalty payments to VBI, subject to achievement of certain activities Transferring manufacturing technologies of BRII-179 and PreHevbrio/PreHevbri to additional manufacturing sites and expanding footp...

2024-02-14 08:07 3622

BioVaxys Acquires All Intellectual Property, Immunotherapeutics Platform Technology, and Clinical Stage Assets of the Former IMV Inc.

VANCOUVER, BC, Feb. 13, 2024 /PRNewswire/ -- BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company") announced that it has executed the definitive Asset Purchase Agreement datedFebruary 11th, 2024 to acquire the entire portfolio of discovery, preclinical and cli...

2024-02-13 03:26 3764

YS Biopharma Announces US$40 Million Private Placement Financing

GAITHERSBURG, Md., Feb. 9, 2024 /PRNewswire/ -- YS Biopharma Co., Ltd. (NASDAQ: YS) ("YS Biopharma") along with its subsidiaries ("YS Group" or the "Company"), a global biopharmaceutical company dedicated to discovering, developing, manufacturing, and delivering new generations of vaccines and th...

2024-02-09 19:30 6103

DKSH Hong Kong Business Unit Healthcare Solidifies Long-Term Partnership with Church & Dwight

DKSH Hong Kong Business Unit Healthcare renews its partnership with Church & Dwight. DKSH continues to provide full agency services with the aim to expand the reach of Church & Dwight's Anusol product range inHong Kong. This collaboration demonstrates DKSH's unwavering commitment to "Healthcare f...

2024-02-08 19:38 2294

DKSH Hong Kong Business Unit Healthcare Solidifies Long-Term Partnership with Church & Dwight

Telix Signs Agreement to Acquire QSAM Biosciences and Its Bone Cancer Targeting Platform

MELBOURNE, Australia , Feb. 8, 2024 /PRNewswire/ --.Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) today announces it has entered into an agreement to acquire QSAM Biosciences, Inc. (U.S. OTC: QSAM) and its lead investigational drug Samarium-153-DOTMP (153Sm-DOTMP). QSAM is a United...

2024-02-08 06:11 1940

Innovent's First New Drug Application of Mazdutide for Chronic Weight Management has been Accepted by the NMPA of China

ROCKVILLE, Md. and SUZHOU, China, Feb. 7, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high-quality medicines for the treatment of oncology, autoimmune, cardiovascular and metabolic...

2024-02-07 16:35 4109

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

SUZHOU, China, Feb. 6, 2024 /PRNewswire/ -- Alphamab Oncology (stock code: 9966.HK) announced that the phase Ⅱclinical research results of anti- PD-L1/CTLA-4 bispecific antibody KN046 in combination with nab-paclitaxel as first-line treatment in advanced triple-negative breast cancer (TNBC) were ...

2024-02-07 09:50 1698

The Results of Phase II Clinical Study of KN046 in Combination with Nab-paclitaxel in TNBC were Published in Nature Communications

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

TOKYO, Feb. 7, 2024 /PRNewswire/ -- SMC Laboratories, Inc. ("SMC Laboratories"), a non-clinical contract research organization (CRO) that provides consulting and contract services for pharmacology studies utilizing technology and know-how related toMetabolic dysfunction associated steatohepatiti...

2024-02-07 02:00 1470

SMC Laboratories Reveals Innovative STAM™-HCC/IO+ Mouse for Identifying and Developing Novel Therapeutic Drugs for Liver Cancer, Blazing a Trail in the Immuno-Oncology Field

TOKYO, Feb. 7, 2024 /PRNewswire/ -- SMC Laboratories, Inc. ("SMC Laboratories"), a non-clinical contract research organization (CRO) that provides consulting and contract services for pharmacology studies utilizing technology and know-how related to Metabolic dysfunction associated steatohepatit...

2024-02-07 02:00 1408

Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

YANTAI, China, Feb. 5, 2024 /PRNewswire/ -- Luye Pharma Group has entered into an agreement with Myung In Pharm, granting the latter the exclusive rights to commercialize Rivastigmine Twice Weekly Transdermal Patch inSouth Korea. Developed by Luye Pharma, this drug is used to treat mild to modera...

2024-02-05 18:53 1726

Luye Pharma Grants Myung In Pharm Exclusive Rights to Commercialize Rivastigmine Twice Weekly Transdermal Patch in South Korea

CARiNG Pharmacy Awarded Gold in Esteemed Putra Aria Brand Awards 2023 in Retail Category

KUALA LUMPUR, Malaysia, Feb. 5, 2024 /PRNewswire/ -- CARiNG Pharmacy proudly announced its victory at the second edition of the prestigious Putra Aria Brand Awards 2023, securing the coveted Gold Award in the Retail Category in recognition of its outstanding contributions to the retail industry. ...

2024-02-05 17:31 1288

Celebrating a Legacy of Care - Pantai Hospital Kuala Lumpur Celebrates 50 Years of Excellence in Healthcare and Unveils Its Future Vision with Gala Dinner

KUALA LUMPUR, Malaysia, Feb. 5, 2024 /PRNewswire/ -- Pantai Hospital Kuala Lumpur (PHKL) marked a significant milestone with its 50th Anniversary Gala Dinner, an event that highlighted the hospital's impressive legacy and future ambitions in the healthcare sector.

2024-02-05 17:01 1644

Celebrating a Legacy of Care - Pantai Hospital Kuala Lumpur Celebrates 50 Years of Excellence in Healthcare and Unveils Its Future Vision with Gala Dinner

Innovent Announces Retirement of CFO and Appointment of New CFO

ROCKVILLE, Md. and SUZHOU, China, Feb. 5, 2024 /PRNewswire/ -- Innovent Biologics, Inc. ("c") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, autoimmune, metabolic, ophthalmology and other ...

2024-02-05 16:45 2443

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

HONG KONG, Feb. 2, 2024 /PRNewswire/ -- Agilis Robotics, a leading innovator in surgical robotics, is spearheading a paradigm shift in the field of "incisionless" endoluminal surgery. The company has made remarkable technological breakthroughs in developing highly miniaturized and flexible robot...

2024-02-05 09:53 1500

Agilis Robotics Unveils Groundbreaking Advancements in Endoluminal Surgery

Lumosa Therapeutics and CHI Memorial announce new study for acute stroke

TAIPEI and CHATTANOOGA, Tenn., Feb. 2, 2024 /PRNewswire/ -- Lumosa Therapeutics (Lumosa; 6535.TWO), together with CHI Memorial have announced the initiation of a Phase2b clinical trial for LT3001, a groundbreaking drug for treating acute stroke. This new drug combines clot-busting and nerve-prote...

2024-02-02 22:22 2535

World Cancer Day 2024: RemeGen Announces Three Significant Developments in the Global Fight Against Cancer, Narrowing the Care Gap

YANTAI, China, Feb. 2, 2024 /PRNewswire/ -- RemeGen Co. Ltd. ("RemeGen" or "the Company") (9995.HK, 688331.SH), a commercial-stage biotechnology company, with a mission that is closely aligned with the Close the Care Gap theme of World Cancer Day 2024 which falls on Febru...

2024-02-02 21:30 1983

Results of Phase II Study on Qilu Pharmaceutical's Novel Drug QL1706 Published in Signal Transduction and Targeted Therapy

JINAN, China, Feb. 2, 2024 /PRNewswire/ -- On January 29th, the results of the phase II study on Qilu Pharmaceutical's novel anticancer drug iparomlimab and tuvonralimab (QL1706) were published online inSignal Transduction and Targeted Therapy (Impact Factor=39.3). The study investigated the use ...

2024-02-02 17:34 1552